

## NIPARK

### Unveiling the biological and physical origins of the neuromelanin-sensitive MRI contrast in rat model and early patients of Parkinson's disease

**Poster number: 16**

**Poster presenter: Jean-Baptiste Pérot**

Jean-Baptiste Pérot, Anthony Ruze, Rahul Gaurav, Sana Rebbah, Capucine Cadin, Zeqian Mao, Arnaud Le Troter, Lucas Soustelle, Laura Mouton, Romain Valabrègue, Annabelle Parent, François-Xavier Lejeune, Isabelle Arnulf, Jean-Christophe Corvol, Marie Vidailhet, Mathieu D. Santin, Miquel Vila, Stéphane Lehericy

#### **Purpose:**

Neuromelanin MRI (NM-MRI) is a promising biomarker of dopaminergic neuron loss in the substantia nigra (SN) in Parkinson's disease (PD). The biological and physical origins of NM-MRI contrast are debated. We quantitatively described the origin of NM signal and longitudinal changes *in vivo* using multiparametric MRI with histological confirmation in a recent AAV-hTyr rat model of PD with accumulation of NM in the SN. We hypothesized that intracellular NM levels may be associated with degeneration in dopaminergic neurons, establishing a threshold for the initiation of PD. Longitudinal NM-MRI in early and prodromal patients of PD is consistent with this hypothesis.

#### **Methods:**

*Preclinical imaging:* Forty rats injected in the right SN with adeno-associated viral vector expressing human tyrosinase (AAV-hTyr) were imaged at 11.7T (Bruker) at 0-, 1-, 2-, 4-, and 8-month post injection (mpi) with acquisition of NM-MRI, quantitative  $R_1$ ,  $R_2$ ,  $R_2^*$ , Quantitative Susceptibility Mapping (QSM), and MPF<sup>8</sup>. Eight rats were euthanized following each imaging session for histological analysis.

*Clinical imaging:* Healthy volunteers (HV), PD patients, and prodromal PD patients (iRBD) were included from the ICEBERG cohort. Participants were followed longitudinally up to 5 years with 2 to 3 imaging sessions, including NM-MRI of the substantia nigra.

#### **Results:**

*AAV-hTyr rats:* Following injection, intracellular and extracellular NM accumulated in the ipsilateral SN. This resulted in increased contrast at 1mpi. Subsequently, intracellular NM continued to increase, extracellular NM reached a plateau, and the number of dopaminergic neurons decreased in the ipsilateral SN (-60% at 4mpi,  $p < 0.001$ ). This resulted in exponential decrease of NM-MRI contrast between 1 and 8mpi.

$R_1$  showed a similar curve to that of NM-MRI, with initial increase (+15% at 1mpi,  $p < 0.001$ ) followed with decrease. Magnetic susceptibility showed continuous increase ( $p < 0.001$  after 2mpi). MPF,  $R_2$ , and  $R_2^*$  did not show significant differences.

*Patients:* PD patients showed reduced NM-MRI SNR in the SN compared with HV and accelerated decrease with time. At the time of onset, 60.9 years old on average, PD patients showed 1.2% reduction of NSI compared to the average NSI in HV. iRBD patients showed a similar curve delayed in time.

#### **Discussion**

The results show that increase in the NM-MRI signal is due to the increase in intra and extracellular NM up to a certain threshold beyond which the NM signal drops due to neurodegeneration of melanized neurons. According to our results, the NM signal is due to a paramagnetic effect of NM-iron complexes which significantly reduce  $T_1$  and increase susceptibility.

Our results show that PD patients present accelerated and early decrease of the signal that suggests neuronal loss. iRBD patients showed a similar decrease delayed in time, which could explain the late onset of PD in these patients. These results are consistent with our hypothesis of a pathogenic threshold of intracellular neuromelanin concentration.

#### **Perspectives**

The role of neuromelanin accumulation and its interaction with iron in the degenerative process in PD needs further investigation. NM-MRI could enable better stratification and may be used as a biomarker for therapeutic evaluation.